A new Hulu series portrays the pharmaceutical industry’s role in the opioid crisis, but how much of it is real and how much is entertainment?

Lumateperone (Caplyta) just got FDA approved for bipolar depression. Find out how it compares to other atypical antipsychotics.

Psychoanalyst Dan Buie, MD, describes 5 deficits that cause great suffering for people with personality disorders and how to work with them in therapy.

Psychoanalyst Dan Buie, MD, describes hateful reactions that are common when working with suicidal patients and how to manage these intense emotions. More in this audio CME.

In 2021 we uncovered some paradoxical effects of medications, including meds that can both cause and treat OCD (antipsychotics), depression (benzodiazepines and antidepressants), and cognitive problems (stimulants and anti-dementia medications).

DHHS recently unveiled the first major overhaul of its documentation guidelines for the E&M codes often used in outpatient psychiatry. We show you how to make those rules work for your patients.

Gordon Parker suggests changes to the DSM-5 criteria for bipolar disorder, and unveils a new screening instrument that aims to separate hypomania from normal happiness.

You will hear about and read research your entire career. Headlines report on positive treatment results, and families come in asking about them. So how should we evaluate research, and what makes a study good or flawed?

For years, we have dreaded seeing our patients develop antipsychotic-induced tardive dyskinesia because there was little we could do about these symptoms. Thankfully, we now have new treatments that produce noticeable improvements in tardive dyskinesia. 

Peter Whitehouse on how to prevent dementia and the limits of pharmacotherapy for cognitive decline. And the word of the day: Ultradian cycling.